{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:57:29Z","timestamp":1791273449367,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Subjects with type 2 diabetes (T2D) have a higher risk of in-stent restenosis and stent thrombosis. The activation of the glucagon-like peptide-1 receptor (GLP-1R) has been suggested to induce several effects on the vasculature that may reduce the risk of stent failure following an angioplasty. The aim of this study is to evaluate the effect of the GLP-1R agonist exenatide on endothelialization of a modern drug-eluting stent (DES) in subjects with T2D.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>38 subjects with T2D who were eligible for revascularization with implantation of DES were randomized to treatment with exenatide (once weekly) plus standard treatment, or to standard treatment alone. After 12\u00a0weeks, a new coronary angiography was performed to evaluate the percentage of strut coverage (primary endpoint) and the presence of neo-atherosclerosis by optical coherence tomography. This study was approved by the Stockholm\u2019s Ethical Review Board.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The two groups were well balanced regarding baseline clinical characteristics. Strut coverage was 95% (88.7\u201398.5%) in the exenatide group and 91.4% (88.8\u201398.5%) in the control group (p\u2009=\u20090.692). There were no significant differences between groups neither in the thickness of neo-intima (0.2\u00a0mm in both groups, p\u2009=\u20090.471), nor the maximal in-stent obstruction by neo-intima (15.5% in exenatide group <jats:italic>vs<\/jats:italic> 14.7% in control group, p\u2009=\u20090.801). No significant differences were detected in the rate of target lesion revascularization between groups (p\u2009=\u20090.224).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Twelve weeks treatment with exenatide did not lead to a significantly better stent coverage in people with T2D. No significant differences in the occurrence of neo-atherosclerosis were detected between groups.<\/jats:p>\n                <jats:p><jats:italic>Trial registration:<\/jats:italic> The study was registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link> (Rebuild Study, NCT02621489).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-02071-4","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T20:01:27Z","timestamp":1702065687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of exenatide on coronary stent\u2019s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct02621489","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Irene","family":"Santos-Pardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Anger\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"18","key":"2071_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"2071_CR2","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.4244\/EIJ-D-21-01034","volume":"18","author":"F Alfonso","year":"2022","unstructured":"Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention. 2022;18(2):e103\u201323.","journal-title":"EuroIntervention"},{"issue":"6","key":"2071_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002328","volume":"8","author":"V Ritsinger","year":"2015","unstructured":"Ritsinger V, Saleh N, Lagerqvist B, Norhammar A. High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 2015;8(6): e002328.","journal-title":"Circ Cardiovasc Interv"},{"issue":"8","key":"2071_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrcardio.2012.64","volume":"9","author":"F Otsuka","year":"2012","unstructured":"Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012;9(8):439\u201353.","journal-title":"Nat Rev Cardiol"},{"issue":"1\u20132","key":"2071_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","volume":"325","author":"O Erdogdu","year":"2010","unstructured":"Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010;325(1\u20132):26\u201335.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2071_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/cvr\/cvw213","volume":"113","author":"S Lim","year":"2017","unstructured":"Lim S, Lee GY, Park HS, Lee DH, Tae Jung O, Kyoung Min K, et al. Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats. Cardiovasc Res. 2017;113(2):183\u201394.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2071_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000381097","volume":"52","author":"L Eriksson","year":"2015","unstructured":"Eriksson L, Saxelin R, Rohl S, Roy J, Caidahl K, Nystrom T, et al. Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury. J Vasc Res. 2015;52(1):41\u201352.\u00a0 https:\/\/doi.org\/10.1159\/000381097","journal-title":"J Vasc Res"},{"issue":"2","key":"2071_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10554-011-9796-3","volume":"27","author":"S Tahara","year":"2011","unstructured":"Tahara S, Chamie D, Baibars M, Alraies C, Costa M. Optical coherence tomography endpoints in stent clinical investigations: strut coverage. Int J Cardiovasc Imaging. 2011;27(2):271\u201387.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"2","key":"2071_CR9","first-page":"143","volume":"15","author":"T Roleder","year":"2019","unstructured":"Roleder T, Kedhi E, Berta B, Gasior P, Wanha W, Roleder M, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: onyx one-month optical coherence tomography study. Postepy Kardiol Interwencyjnej. 2019;15(2):143\u201350.","journal-title":"Postepy Kardiol Interwencyjnej"},{"issue":"2","key":"2071_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/ehjci\/jew070","volume":"18","author":"M Iannaccone","year":"2017","unstructured":"Iannaccone M, D\u2019Ascenzo F, Templin C, Omede P, Montefusco A, Guagliumi G, et al. Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2017;18(2):159\u201366.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9","key":"2071_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2071_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s10554-013-0223-9","volume":"29","author":"H Won","year":"2013","unstructured":"Won H, Shin DH, Kim BK, Mintz GS, Kim JS, Ko YG, et al. Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation. Int J Cardiovasc Imaging. 2013;29(6):1255\u201363.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"6","key":"2071_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jcin.2010.04.005","volume":"3","author":"G Guagliumi","year":"2010","unstructured":"Guagliumi G, Sirbu V, Bezerra H, Biondi-Zoccai G, Fiocca L, Musumeci G, et al. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. JACC Cardiovasc Interv. 2010;3(6):680\u20137.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"2071_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12933-022-01460-5","volume":"21","author":"S Wilson","year":"2022","unstructured":"Wilson S, Mone P, Kansakar U, Jankauskas SS, Donkor K, Adebayo A, et al. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21(1):23.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2071_CR15","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00380-015-0737-2","volume":"31","author":"D Izumi","year":"2016","unstructured":"Izumi D, Miyahara M, Fujimoto N, Fukuoka S, Sakai M, Dohi K, et al. Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation. Heart Vessels. 2016;31(8):1247\u201356.","journal-title":"Heart Vessels"},{"issue":"5","key":"2071_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008869","volume":"13","author":"H Jinnouchi","year":"2020","unstructured":"Jinnouchi H, Otsuka F, Sato Y, Bhoite RR, Sakamoto A, Torii S, et al. Healthy strut coverage after coronary stent implantation: an ex vivo human autopsy study. Circ Cardiovasc Interv. 2020;13(5): e008869.","journal-title":"Circ Cardiovasc Interv"},{"key":"2071_CR17","doi-asserted-by":"crossref","unstructured":"Tamez H, Secemsky EA, Valsdottir LR, Moussa ID, Song Y, Simonton CA, et al. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention. 2021;17(5):e380\u20137.","DOI":"10.4244\/EIJ-D-19-01031"},{"issue":"6","key":"2071_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1161\/CIRCINTERVENTIONS.114.001341","volume":"7","author":"MA Magalhaes","year":"2014","unstructured":"Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, et al. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circ Cardiovasc Interv. 2014;7(6):768\u201376.","journal-title":"Circ Cardiovasc Interv"},{"key":"2071_CR19","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.2147\/IJN.S211898","volume":"14","author":"CH Lee","year":"2019","unstructured":"Lee CH, Hsieh MJ, Chang SH, Hung KC, Wang CJ, Hsu MY, et al. Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo. Int J Nanomedicine. 2019;14:7503\u201313.","journal-title":"Int J Nanomedicine"},{"key":"2071_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijcard.2021.02.011","volume":"330","author":"I Santos-Pardo","year":"2021","unstructured":"Santos-Pardo I, Lagerqvist B, Ritsinger V, Witt N, Norhammar A, Nystrom T. Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: a nationwide observational study. Int J Cardiol. 2021;330:23\u20139.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2071_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","volume":"21","author":"R Marfella","year":"2023","unstructured":"Marfella R, Sardu C, D\u2019Onofrio N, Fumagalli C, Scisciola L, Sasso FC, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21(1):71.","journal-title":"BMC Med"},{"issue":"4","key":"2071_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.006034","volume":"11","author":"SWL Lee","year":"2018","unstructured":"Lee SWL, Tam FCC, Lam SCC, Kong SL, Shea CP, Chan KKW, et al. The OCT-ORION Study: a randomized optical coherence tomography study comparing resolute integrity to biomatrix drug-eluting stent on the degree of early stent healing and late lumen loss. Circ Cardiovasc Interv. 2018;11(4): e006034.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"2071_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00380-014-0598-0","volume":"31","author":"T Hashikata","year":"2016","unstructured":"Hashikata T, Tojo T, Namba S, Kitasato L, Hashimoto T, Kameda R, et al. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months\u2019 follow-up: an optical coherence tomography study. Heart Vessels. 2016;31(2):206\u201311.","journal-title":"Heart Vessels"},{"issue":"1","key":"2071_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2012.08.037","volume":"111","author":"S Kim","year":"2013","unstructured":"Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, et al. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol. 2013;111(1):1\u20135.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2071_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41569-018-0118-5","volume":"16","author":"T Gori","year":"2019","unstructured":"Gori T, Polimeni A, Indolfi C, Raber L, Adriaenssens T, Munzel T. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol. 2019;16(4):243\u201356.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2071_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jacc.2022.05.017","volume":"80","author":"G Giustino","year":"2022","unstructured":"Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, et al. Coronary In-Stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(4):348\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2071_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.118.007023","volume":"12","author":"E Shlofmitz","year":"2019","unstructured":"Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv. 2019;12(8): e007023.","journal-title":"Circ Cardiovasc Interv"},{"issue":"13","key":"2071_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"2071_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"2071_CR30","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2071_CR31","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"10193","key":"2071_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10","key":"2071_CR33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"7","key":"2071_CR34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374.","journal-title":"Nat Rev Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02071-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-02071-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02071-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T20:02:49Z","timestamp":1702065769000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-02071-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2071"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-02071-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects gave their written consent to participate in the trial. The study was approved by the Ethical Review Board of the Stockholm County Regional Council, the Medical Products Agency and the Swedish Radiation Safety Authority and complies with the current ICH E6 (R2), good clinical practice guidelines and the Helsinki declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TN has received unrestricted grants from AstraZeneca and NovoNordisk and has served on national advisory boards of Amgen, Abbot, Novo Nordisk, Sanofi-Aventis, Eli Lilly, MSD and Boehringer Ingelheim. OA has received a research grant and a personal lecture fee from Abbott Vascular. ISP and NW declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"337"}}